Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma

Diffuse large B cell lymphoma (DLBCL) is one of the most usual types of adult lymphoma with heterogeneousness in histological morphology, prognosis, and clinical indications. Prior to this, several studies were carried out to determine the DLBCL subtype based on the analysis of the genome profile. H...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2022-08, Vol.2022, p.1-16
Main Authors: Wang, Longhao, Yuan, Wei, Li, Lifeng, Shen, Zhibo, Geng, Qishun, Zheng, Yuanyuan, Zhao, Jie
Format: Article
Language:English
Subjects:
Antibodies
B-cell lymphoma
CD4 antigen
CD8 antigen
Cell culture
Correlation analysis
Flow cytometry
Gene expression
Genomes
Genomic analysis
Genomics
Histocompatibility antigen HLA
Immune checkpoint
Immune response
Immunohistochemistry
Immunological memory
Immunology
Immunotherapy
Interferon regulatory factor 4
Lymphocytes T
Lymphoma
Macrophages
Medical prognosis
Memory cells
Monocytes
Patients
Peripheral blood
siRNA
Software
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diffuse large B cell lymphoma (DLBCL) is one of the most usual types of adult lymphoma with heterogeneousness in histological morphology, prognosis, and clinical indications. Prior to this, several studies were carried out to determine the DLBCL subtype based on the analysis of the genome profile. However, classification based on assessment of genes related to the immune system has limited clinical significance for DLBCL. We systematically explored the DLBCL gene expression dataset and provided publicly available clinical information on patients with GEO. In this research, 928 DLBCL samples were applied, and we calculated 29 immune-related genomes’ enrichment levels in each sample and stratified them into high immunity (Immunity_H, n=135, 28.7%), moderate immunity (Immunity_M, n=135, 28.7%), and low immunity (Immunity_L, n=12, 2.6%) that was based on ssGSEA score. The ESTIMATE algorithm was used to calculate stromal scores (range 586.88 to 1982.43), immune scores, estimated scores (range 2,618.2 to 8,098.14), and tumor purity (range 0.216 to 0.976). All of them were significantly correlated with immune subtypes (Kruskal-Wallis test, p
ISSN:2314-8861
2314-7156
DOI:10.1155/2022/9544827